Home

Bli medveten om Skära Bil rhovac ab spotlight Sopa Väsentlig Värdelös

Technical Analysis | Spotlight
Technical Analysis | Spotlight

Immuno-oncology | BioWorld
Immuno-oncology | BioWorld

Chosa ApS completed the acquisition of RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction. -January 17, 2023 | MarketScreener
Chosa ApS completed the acquisition of RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction. -January 17, 2023 | MarketScreener

Delårsrapport 2018-01-01 – 2018-09-30 RhoVac AB
Delårsrapport 2018-01-01 – 2018-09-30 RhoVac AB

Rhovac – Revolutionerar immunologisk cancerbehandling | Redeye
Rhovac – Revolutionerar immunologisk cancerbehandling | Redeye

RhoVac – Stora Aktiedagen Stockholm 30 november 2021 - YouTube
RhoVac – Stora Aktiedagen Stockholm 30 november 2021 - YouTube

Inbjudan till att teckna konvertibler i RhoVac AB (publ) Teckningsperiod 17–31 mars 2022
Inbjudan till att teckna konvertibler i RhoVac AB (publ) Teckningsperiod 17–31 mars 2022

RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac — Stopping metastasis in its tracks - Edison Group

Chosa Oncology — Making headway in precision oncology - Edison Group
Chosa Oncology — Making headway in precision oncology - Edison Group

RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac — Stopping metastasis in its tracks - Edison Group

Sista dag för handel med BTA 23 juli 2019 - IPO.se
Sista dag för handel med BTA 23 juli 2019 - IPO.se

RhoVac AB will be transferred to Spotlight Stock Market's observation list
RhoVac AB will be transferred to Spotlight Stock Market's observation list

RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac — Stopping metastasis in its tracks - Edison Group

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA
RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Technical Analysis | Spotlight
Technical Analysis | Spotlight

RhoVac receives approval in Sweden to start clinical phase IIb trial
RhoVac receives approval in Sweden to start clinical phase IIb trial

Chosa Oncology — Making headway in precision oncology - Edison Group
Chosa Oncology — Making headway in precision oncology - Edison Group

Immuno-Oncologic Drug Patent Protection Extended — Precision Vaccinations News
Immuno-Oncologic Drug Patent Protection Extended — Precision Vaccinations News

FUTURE ANTI-CANCER DRUGS
FUTURE ANTI-CANCER DRUGS

RhoVac announces the completion of patient recruitment for the BRaVac clinical phase IIb study of RV001 in prostate cancer
RhoVac announces the completion of patient recruitment for the BRaVac clinical phase IIb study of RV001 in prostate cancer

ÅRSREDOVISNING & KONCERNREDOVISNING RHOVAC AB
ÅRSREDOVISNING & KONCERNREDOVISNING RHOVAC AB

RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac — Stopping metastasis in its tracks - Edison Group

RhoVac AB | Nordic Issuing
RhoVac AB | Nordic Issuing

RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac — Stopping metastasis in its tracks - Edison Group

RhoVac AB conducts conditional reverse takeover of Chosa ApS
RhoVac AB conducts conditional reverse takeover of Chosa ApS

Nyemission Chosa Oncology AB på - Aktier
Nyemission Chosa Oncology AB på - Aktier

RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac — Stopping metastasis in its tracks - Edison Group

Chosa ApS completed the acquisition of RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction. -January 17, 2023 | MarketScreener
Chosa ApS completed the acquisition of RhoVac AB from M2 Asset Management AB and others in a reverse merger transaction. -January 17, 2023 | MarketScreener

RhoVac AB changes name to CHOSA Oncology AB
RhoVac AB changes name to CHOSA Oncology AB

RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial
RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial